Get the Stockscreener App
79.12
0.06%
-0.05
After Hours:
79.12
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $79.12, with a volume of 3.00M.
It is down -0.06% in the last 24 hours and up +15.02% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$79.17
Open:
$79.485
24h Volume:
3.00M
Relative Volume:
0.66
Market Cap:
$245.38B
Revenue:
$56.53B
Net Income/Loss:
$8.32B
P/E Ratio:
29.52
EPS:
2.6798
Net Cash Flow:
$8.49B
1W Performance:
+6.82%
1M Performance:
+15.02%
6M Performance:
+5.78%
1Y Performance:
-6.27%
1-Day Range:
$79.10
$79.78
1-Week Range:
$74.04
$79.78
52-Week Range:
$61.24
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
79.12 | 245.47B | 56.53B | 8.32B | 8.49B | 2.6798 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
AstraZeneca Receives Chinese Approval to Acquire FibroGen China - MarketScreener
AstraZeneca CFO Aradhana Sarin sells 9,563 shares in London transaction - Investing.com
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation - GlobeNewswire Inc.
AstraZeneca (LSE:AZN) Launches FluMist Home For At-Home Influenza Vaccination - uk.finance.yahoo.com
AstraZeneca’s CKD Registry Study: A Strategic Move in Nephrology - MSN
AstraZeneca’s Promising Study on Durvalumab and Olaparib in Advanced Bladder Cancer - MSN
AstraZeneca’s Phase I Study on Balcinrenone/Dapagliflozin: Key Insights for Investors - MSN
AstraZeneca’s Phase III Study: Baxdrostat and Dapagliflozin Combination for Heart Failure Prevention - MSN
Wholesalers Want Final OK For $51M AstraZeneca Settlement - Law360
AstraZeneca Launches At-Home Flu Vaccine Amid Industry DTC Push - insights.citeline.com
AstraZeneca’s Innovative Approach in Cancer Treatment: A Study Update - TipRanks
AstraZeneca’s Promising Phase 1 Study on AZD0486 for B-Cell Non-Hodgkin Lymphoma - TipRanks
AstraZeneca’s New Study on Anifrolumab: What Investors Need to Know - TipRanks
AstraZeneca’s EROS+CP Japan Study: Key Insights for Investors - TipRanks
AstraZeneca’s TRITON Study: A New Frontier in NSCLC Treatment - TipRanks
AstraZeneca’s Selumetinib Study Update: Potential Game-Changer for KRAS-Positive NSCLC - TipRanks
AstraZeneca’s ZEAL Study Termination: Implications for Investors - TipRanks
AstraZeneca’s Anifrolumab Pregnancy Study: A New Chapter in SLE Treatment - TipRanks
AstraZeneca’s APPRECIATE Study: A New Hope for APOL1-Mediated Kidney Disease - TipRanks
Capital Group Increases Stake in AstraZeneca - TipRanks
AstraZeneca’s CAPItello-292 Study: A New Frontier in Breast Cancer Treatment - TipRanks
AstraZeneca’s Asthma Study: Key Insights for Investors - TipRanks
AstraZeneca’s LATIFY Study: A New Hope for NSCLC Treatment? - TipRanks
AstraZeneca’s ESPERANZA Study: Real-World Insights into T-DXd for HER2 IHC3+ Tumors - TipRanks
AstraZeneca’s Clinical Study on BGF MDI: Recent Developments and Market Impact - TipRanks
AstraZeneca’s EPIC-ATTR Study: A Potential Game-Changer in Cardiomyopathy Treatment - TipRanks
AstraZeneca and ModernaTX Complete Promising Phase 1 Cancer Study - TipRanks
AstraZeneca’s AQUALIS Study: Enhancing Quality of Life for CLL Patients - TipRanks
AstraZeneca’s New Study on Kidney Disease Drug Combo: What Investors Need to Know - TipRanks
AstraZeneca’s AZD7798 Study: A Potential Game-Changer for Crohn’s Disease Treatment - TipRanks
AstraZeneca’s DAISY Study: A New Hope for Systemic Sclerosis Treatment - TipRanks
AstraZeneca’s New Study: Exploring Ceralasertib’s Impact on Drug Interactions - TipRanks
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs - The Globe and Mail
AstraZeneca’s New Study on Personalized Asthma Treatments in China: Market Implications - MSN
AstraZeneca Launches At-Home Delivery Service for Flu Vaccine - MarketScreener
AstraZeneca Launches At-Home Delivery Service for Nasal Spray Flu Vaccine - MarketScreener
AstraZeneca launches first FDA-approved at-home flu vaccine - Investing.com
AstraZeneca Launches At-Home FluMist as Vaccination Rate Drops - Bloomberg.com
AstraZeneca’s Phase 3 Study on Anifrolumab for Systemic Lupus Erythematosus: A Market Game Changer? - MSN
AstraZeneca’s Pediatric Hyperkalaemia Study: A Potential Market Game-Changer - MSN
AstraZeneca’s Latest Study on Balcinrenone/Dapagliflozin: Key Insights for Investors - TipRanks
George Soros Exits AstraZeneca PLC, Impacting Portfolio by -3.98% - Yahoo Finance
AstraZeneca’s Observational Study on Bladder Cancer Biomarkers in Russia: Key Insights for Investors - TipRanks
Soros Fund Management dissolves share stake in AstraZeneca, reports sponsored ADS stake in TSMC - MarketScreener
AstraZeneca’s Promising Phase 3 Study on Mantle Cell Lymphoma Treatment - TipRanks
Real Time Data Flags Unusual Activity in AstraZeneca PLC Depositary ReceiptNew Guidance & Low Risk Profit Maximizing Plans - beatles.ru
AstraZeneca’s ROSY-D Study: Extending Benefits of Durvalumab in Oncology - TipRanks
AstraZeneca’s New Study on AZD0305: Potential Breakthrough in Multiple Myeloma Treatment? - TipRanks
AstraZeneca’s iCaReMe Global Registry: A Real-World Study on Chronic Disease Management - TipRanks
AstraZeneca’s Real-World Study on Tezepelumab: A Potential Game-Changer for Severe Asthma - TipRanks
AstraZeneca’s Phase III Breast Cancer Study: A Potential Game Changer? - TipRanks
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):